LUNG Key Statistics, Chart & Performance
The current stock price of LUNG is 2.01 USD. In the past month the price increased by 11.05%. In the past year, price decreased by -68.59%.
LUNG Latest News, Press Relases and Analysis
LUNG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.07 | 217.50B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.82 | 203.96B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.06 | 144.57B | ||
| SYK | STRYKER CORP | 27.64 | 139.21B | ||
| IDXX | IDEXX LABORATORIES INC | 56.63 | 57.02B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.54 | 50.02B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.62 | 38.93B | ||
| RMD | RESMED INC | 25.91 | 37.45B | ||
| DXCM | DEXCOM INC | 35.21 | 25.54B | ||
| PODD | INSULET CORP | 66.63 | 21.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.65 | 18.68B |
Related stock screener links
About LUNG
Company Profile
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 291 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Company Info
PULMONX CORP
700 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Glendon E. French
Employees: 291
Phone: 16509342600
PULMONX CORP / LUNG FAQ
What does LUNG do?
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 291 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
What is the current price of LUNG stock?
The current stock price of LUNG is 2.01 USD. The price decreased by -6.07% in the last trading session.
Does LUNG stock pay dividends?
LUNG does not pay a dividend.
What is the ChartMill technical and fundamental rating of LUNG stock?
LUNG has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists LUNG stock?
LUNG stock is listed on the Nasdaq exchange.
What is PULMONX CORP worth?
PULMONX CORP (LUNG) has a market capitalization of 82.91M USD. This makes LUNG a Micro Cap stock.
What is the ownership structure of PULMONX CORP (LUNG)?
You can find the ownership structure of PULMONX CORP (LUNG) on the Ownership tab.
LUNG Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LUNG. When comparing the yearly performance of all stocks, LUNG is a bad performer in the overall market: 88.22% of all stocks are doing better.
LUNG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LUNG. LUNG may be in some trouble as it scores bad on both profitability and health.
LUNG Financial Highlights
Over the last trailing twelve months LUNG reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 1.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.04% | ||
| ROE | -94.54% | ||
| Debt/Equity | 0.62 |
LUNG Forecast & Estimates
12 analysts have analysed LUNG and the average price target is 5.87 USD. This implies a price increase of 191.79% is expected in the next year compared to the current price of 2.01.
For the next year, analysts expect an EPS growth of -7.1% and a revenue growth 8.99% for LUNG